Abstract
Findings show brain serotonin (5-hydroxytryptamine (5-HT)) activity to be altered in individuals who have had bulimia nervosa (BN), even after substantial remission of symptoms. Such findings could reflect persistent sequelae due to BN, or a vulnerability ‘trait’ that exists independently of active eating-disorder manifestations. We compared women with full-blown BN (BN; n=22), BN in remission (BN-R; n=11), and no eating or psychiatric disturbances (n=22) on measures of platelet [3H]paroxetine binding, eating symptoms and psychopathology. The BN-R group showed normal-range scores on eating and psychopathological symptoms, but reductions in density (Bmax) of binding sites for paroxetine similar to those obtained in the actively ill women. Both BN groups had substantially lower Bmax than did healthy controls. Our results corroborate other findings indicating recovered BN patients to have anomalous 5-HT functioning. While such effects could represent a lasting ‘injury’ to the system, reported covariations between personality traits and 5-HT indices in BN encourage us to favor the argument that some alterations of 5-HT activity (in this case, consistent with reduced transporter activity) represent a ‘trait’ associated with the risk of developing BN and/or associated psychopathology.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC.
Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L et al (2004). Altered 5-HT (2A) receptor binding after recovery from bulimia type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 29: 1143–1155.
Bucholz KK, Robins LN, Shayka JJ, Przybeck TR, Heltzer JE, Goldring E et al (1991). Performance of two forms of a computer psychiatric screening interview: Version 1 of the DISSI. J Psychiatr Res 25: 117–129.
Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975–990.
Coccaro E, Kavoussi RJ, Sheline YI, Lish JD, Csernansky JG (1996). Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 53: 531–536.
Fairburn C, Cooper P (1993). The eating disorders examination. In: Fairburn C, Wilson G (eds). Binge Eating: Nature, Assessment and Treatment, 12th edn. Guilford: New York. pp 317–360.
Freeman A, Stankovic S, Bradley R, Zhang G-Z, Libb J, Nemeroff C (1993). Tritiated platelet imipramine binding and treatment response in depressed outpatients. Depression 1: 20–23.
Garner DM (1991). Eating Disorder Inventory-2: Professional Manual. Psychological Assessment Resources: Odessa, FL.
Garner DM, Olmsted M, Bohr Y, Garfinkel P (1982). The eating attitudes test: psychometric features and clinical correlates. Psychol Med 12: 871–878.
Goodwin GM, Fraser S, Stump K, Fairburn CG, Elliot JM, Cowen PJ (1987). Dieting and weight loss in volunteers increases the number of alpha2-adenoreceptors and 5-HT receptors on blood platelets without effect on [3H]-imipramine binding. J Affect Disord 12: 267–274.
Huether G, Zhou D, Schmidt S, Wiltfang J, Rüther E (1997). Long-term food restriction down regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry 41: 1174–1180.
Jimerson DC, Lesem MD, Kaye WH, Brewerton TD (1992). Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 49: 132–138.
Kaye WH, Frank GK, Meltzer CM, Price JC, McConaha CW, Crossan PJ et al (2001). Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 158: 1152–1155.
Kaye WH, Greeno CG, Moss H, Fernstrom JD, Fernstrom MH, Lilenfeld LR et al (1998). Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch Gen Psychiatry 55: 927–935.
Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993). Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319–2322.
Levitan RD, Kaplan AS, Joffe RT, Levitt AJ, Brown GM (1997). Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiatry 54: 521–527.
Lilenfeld LR, Stein D, Bulik CM, Strober M, Plotnicov K, Pollice C et al (2000). Personality traits among currently eating disordered, recovered and never ill first-degree female relatives of bulimic and control women. Psychol Med 30: 1399–1410.
Livesley WJ, Jackson DN, Schroeder ML (1992). Factorial structure of traits delineating personality disorders in clinical and general population samples. J Abnormal Psychol 101: 432–440.
Marazziti D, Macchi E, Rotondo A, Placidi GF, Cassano GB (1988). Involvement of the serotonin system in bulimia. Life Sci 43: 2123–2126.
Patton JH, Stanford MS, Barrat ES (1995). Factor structure of the Barrat Impulsiveness Scale. J Clin Psychol 51: 768–774.
Robins LN, Heltzer JE, Croughan J, Ratcliff KS (1981). National institute of mental health diagnostic interview schedule. Arch Gen Psychiatry 38: 381–389.
Smith KA, Fairburn CG, Cowen PJ (1999). Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. Arch Gen Psychiatry 56: 171–176.
Steiger H, Joober R, Israël M, Young SN, Ng Ying Kin NMK, Gauvin L et al (2005). The 5HTTLPR polymorphism, psychopathological symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eating Disord 1: 57–60.
Steiger H, Koerner NM, Engleberg M, Israël M, Ng Ying Kin NMK, Young SN (2001a). Self-destructiveness and serotonin function in bulimia nervosa. Psychiatry Res 103: 15–26.
Steiger H, Leonard S, Ng Ying Kin NMK, Ladouceur C, Ramdoyal D, Young SN (2000). Childhood abuse and tritiated paroxetine binding in bulimia nervosa. J Clin Psychiatry 61: 428–435.
Steiger H, Young SN, Ng Ying Kin NMK, Koerner N, Israel M, Lageix P et al (2001b). Implications of impulsive and affective symptoms for serotonin function in bulimia nervosa. Psychol Med 31: 85–95.
Tauscher J, Pirker W, Willeit M, de Zwaan M, Bailer U, Neumeister A et al (2001). Beta-CIT and single photon emission computer tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry 49: 326–332.
Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ (1977). Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 106: 203–214.
Wolfe BE, Metzger ED, Levine JM, Finkelstein DM, Cooper TB, Jimerson DC (2000). Serotonin function following remission from bulimia nervosa. Neuropsychopharmacology 22: 257–263.
Zhou D, Huether G, Wiltfangt J, Hajak G, Ruther E (1996). Serotonin transporters in the rat frontal cortex: lack of circadian rythmicity but down-regulation by food restriction. J Neurochem 67: 656–661.
Acknowledgements
This research was supported by a grant from the Canadian Institutes for Health Research (No. MA 15368). Preliminary results from this study were presented at the annual meeting of the Eating Disorders Research Society, Amsterdam, the Netherlands, October 9, 2004. We thank Debra Gartenberg, Leechen Faarkas, Heidi Shapiro, Julia Finkelstein, Andrea Byrne, Stephanie Levine-Grant, Melanie Aubut, and Susan Amro for their contributions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Steiger, H., Richardson, J., Israel, M. et al. Reduced Density of Platelet-Binding Sites for [3H]Paroxetine in Remitted Bulimic Women. Neuropsychopharmacol 30, 1028–1032 (2005). https://doi.org/10.1038/sj.npp.1300693
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300693
